What Zentiva does

Zentiva is a European pharmaceutical company that develops, manufactures, and distributes high-quality, affordable generic and branded generic medicines, over-the-counter (OTC) consumer healthcare products, and biosimilars. Its portfolio spans 1,826+ product items covering cardiology, oncology, respiratory, central nervous system, and diabetes therapeutic areas, serving more than 100 million people across 40+ countries in Europe and beyond. The company operates four owned manufacturing plants in Czech Republic, Romania (two sites), and India, producing 718 million Standard Manufacturing Units annually, supplemented by a network of external manufacturing partners. Its R&D footprint comprises two centers with 250+ experts registered 509 new product filings in 2025, supported by an Open Innovation Program and the PARC academic partnership through Prague Scientific.

Zentiva generates revenue across four primary streams: prescription generic and branded generic medicines sold through 31 active branches and 6 representations by 1,800+ medical representatives; OTC and consumer healthcare products distributed through pharmacies and retail; the Zent2U B2B platform offering API supply, CDMO services, and know-how licensing; and Prague Scientific pharmacovigilance and regulatory services. The company positions itself as a cost-effective alternative to originator brands, supporting healthcare system sustainability across European markets. Pricing is regulated by national healthcare authorities, with quote-based and contract-based terms for institutional customers and public procurement organizations.

Founded in 1993 after the Velvet Revolution, with pharmaceutical roots tracing to 1488 in Prague, Zentiva was publicly listed (2004), merged with Sanofi (2008), spun off to Advent International (2018), and most recently acquired by GTCR in April 2026. Under current ownership, the company employs 5,400+ professionals across 30+ countries and has expanded aggressively through acquisitions (Creo Pharmaceuticals, Solacium, Alvogen CEE, Helvepharm, Ankleshwar plant, Aboca OTC brands) and licensing partnerships (mAbxience biosimilars, Adalvo, Lupin). Recent strategic moves include the Lupin biosimilar deal and Aboca OTC acquisition in 2025, with a stated goal to reach 1 in 5 people in Europe by 2028.

Name

Zentiva

Legal name

Zentiva Group, a.s.

Website

https://zentiva.sk

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

11–50 employees

Short description

Zentiva is a European pharmaceutical company developing, manufacturing, and supplying generic, branded generic, OTC, and biosimilar medicines, serving 100+ million patients across 40+ countries through 31 branches and 1,800+ medical representatives.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industries

Respiratory & Allergy Pharmaceuticals (HLAIAAAH), Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO), Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)

Keywords

• Generic pharmaceuticals
• Branded generic medicines
• OTC consumer healthcare
• API manufacturing services
• Biosimilar medicines

Headquarters

HQ city

Bratislava

Offices31 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Generic and Branded Generic Medicines (Rx): Prescription generic and branded generic medicines covering therapeutic areas including cardiology, oncology, respiratory, CNS, and diabetes. Products include original brands protected by patents or data exclusivity, and branded generics serving as equivalent alternatives to originator products. Revenue generated through direct sales to healthcare providers, pharmacies, and public procurement across Europe.
2. OTC and Consumer Healthcare Products: Over-the-counter products and nutritional supplements sold through pharmacies and retail channels, including natural-based OTC products acquired from Aboca in 2025. Revenue from consumer-facing OTC sales across European markets.
3. B2B Platform Services (Zent2U): Specialized B2B platform offering API (active pharmaceutical ingredient) supply, CDMO (contract development and manufacturing) services, and licensing of know-how to partners, with deep expertise in cardiology, urology, oncology, neurology, and hormonal therapies.
4. Scientific and Regulatory Services (Prague Scientific): High-quality pharmacovigilance and regulatory services for prescription drugs (Rx), OTC, and non-drug products through Prague Scientific, supporting every phase of the drug lifecycle from concept to product compliance maintenance.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

Zentiva develops, manufactures, and supplies high-quality, affordable generic and branded generic prescription medicines, over-the-counter (OTC) consumer healthcare products, and biosimilars across therapeutic areas including cardiology, oncology, respiratory, CNS, and diabetes. The company maintains a portfolio of 1,826+ product items, produced at four owned manufacturing plants in the Czech Republic, Romania, and India, and distributed across 40+ countries to over 100 million people via 31 commercial branches and 1,800+ medical representatives. It also operates the Zent2U B2B platform for API supply, CDMO services, and licensing, and Prague Scientific for pharmacovigilance and regulatory services.

Product overview

Zentiva is a European pharmaceutical company developing, manufacturing, and supplying high-quality, affordable medicines. Its portfolio consists of prescription (Rx) medicines and over-the-counter (OTC) consumer healthcare products across therapeutic areas including cardiology, oncology, respiratory care, CNS, and diabetes. The offering is structured around branded generic medicines and specialized products, supported by two core B2B service platforms: Zent2U (providing API supply, CDMO services, and outlicensing) and Prague Scientific (providing R&D, manufacturing, pharmacovigilance, and regulatory affairs services). The company also operates an Open Innovation Program and research partnerships including PARC. In 2024, more than 140 new products were launched, and the company maintains 1,826+ product items serving over 100 million people across 40+ countries.

Differentiator

Problem solved

Functional benefit

Brands

• Zent2U: Specialized B2B platform offering API, CDMO services, and licensing of know-how to partners in key therapeutic areas including cardiology, urology, oncology, neurology, and hormonal treatments
• Prague Scientific

Products and services

• Branded Generic Medicines (Rx) Prescription branded generic medicines covering cardiology, oncology, respiratory, CNS, and diabetes therapeutic areas, positioned as cost-effective alternatives to originator products for healthcare providers, pharmacies, and public procurement organizations across Europe.
• OTC and Consumer Healthcare Products Over-the-counter medications, natural-based products, and nutritional supplements sold through pharmacies and retail channels across European markets, including brands acquired from Aboca in 2025.
• Biosimilar Medicines Biosimilar products co-developed with mAbxience and licensed from Lupin, commercialized across European markets to expand access to biologic therapies.
• Zent2U B2B Platform Specialized B2B platform offering API (Active Pharmaceutical Ingredient) supply, CDMO (Contract Development and Manufacturing Organization) services, and outlicensing of proprietary know-how to pharmaceutical partners, with deep expertise in cardiology, urology, oncology, neurology, and hormonal therapies.
• Prague Scientific Comprehensive development and scientific services supporting every phase of the drug lifecycle from concept to market compliance, including API and formulation R&D, manufacturing, pharmacovigilance, and regulatory affairs.
• API Supply and CDMO Manufacturing Services Active Pharmaceutical Ingredient (API) supply and contract development and manufacturing services provided to pharmaceutical companies through Zentiva's four owned plants and external manufacturing network.

Quantifiable outcome

• 100+ million people served across 40+ countries in Europe and beyond
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• LupincoreStrategic or Co-development Partner · 1 January 2025Zentiva and Lupin signed a licensing and supply agreement for a biosimilar TNF-alpha inhibitor drug in 2025, expanding biosimilar portfolio offerings.
• AbocaminorStrategic or Co-development Partner · 1 January 2025Zentiva acquired original brands from Aboca in 2025 to expand the OTC portfolio of natural-based products across Europe.
• AdalvocoreStrategic or Co-development Partner · 1 January 2023Zentiva and Adalvo signed a licensing agreement for therapeutic areas of respiratory medicine, CNS, and dermatology across Europe in 2023, strengthening Zentiva's portfolio in these key therapeutic areas.
• mAbxiencecoreStrategic or Co-development Partner · 1 January 2021Launch of first biosimilar medicine in collaboration with mAbxience across 21 countries in Europe in 2021, representing a significant strategic partnership for biosimilar development and commercialization.
• PARC (Pharmaceutical Applied Research Centre)coreStrategic or Co-development PartnerAcademic partnership through Prague Scientific with PARC (Pharmaceutical Applied Research Centre) for applied pharmaceutical research, combining scientific excellence with creativity and bold thinking to deliver high-quality, affordable medicines.
• BusinessEuropeminorStrategic or Co-development PartnerZentiva collaborates with BusinessEurope as a member of the advisory and support group, engaging in dialogues to shape competitive and sustainable EU industrial policy with a focus on safe medicine manufacturing and supply chains.
• Medicines for EuropecoreStrategic or Co-development PartnerZentiva is a proud member of Medicines for Europe, which represents pharmaceutical companies supplying the largest share of medicines in Europe. Actively contributes as a member of the executive team, board, and several committees. Adheres to the Code of Conduct ensuring ethical marketing practices.
• Genas (Generické a biosimilárne lieky)minorStrategic or Co-development PartnerZentiva is a member of Genas, the Slovak Association for Generic and Biosimilar Medicines, which unites 13 pharmaceutical companies and advocates for accessible and sustainable treatment for patients and healthcare system sustainability.

Scale indicators15 records

Recent moves13 records

Expansion highlights7 records

Direct peers

• Krka: Slovenian generic pharma manufacturer with strong CEE, Eastern European, and Western European presence and similar therapeutic focus in cardiovascular, CNS, and oncology—directly comparable to Zentiva's CEE origins and branded generic strategy.
• Stada Arzneimittel: PE-owned European generic pharma and consumer healthcare company with similar product portfolio across cardiology, oncology, and CNS, plus extensive Eastern European footprint—closely comparable to Zentiva's franchise model and CEE-heavy presence.
• Viatris: Global generics and specialty pharma formed from Mylan and Upjohn, with broad generic and biosimilar portfolio across Europe and emerging markets—directly comparable across therapeutic areas and contract manufacturing services.
• Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer with extensive European presence across branded generics, specialty, and biosimilars—directly comparable to Zentiva's portfolio breadth, therapeutic area focus, and large-scale manufacturing footprint.
• Sandoz: Novartis's generics and biosimilars spinoff, a leading European generic pharma with broad small-molecule portfolio, biosimilar pipeline, and pan-European distribution—directly comparable to Zentiva's branded generics and Zent2U CDMO model.

Regional players

• Polpharma: Polish-based generic pharma manufacturer with strong CEE presence and API manufacturing capabilities—comparable to Zentiva's CEE focus and API/CDMO offering but more regionally concentrated.

Broad incumbents

• Hikma Pharmaceuticals: MENA-rooted global pharma with strong European generics business; comparable in broad generic portfolio and injectables focus, although the geographic mix differs from Zentiva's European-centric footprint.
• Aurobindo Pharma: Indian-headquartered global generic pharma with pan-European distribution and API manufacturing—comparable to Zentiva's European generic channel and Ankleshwar/API capabilities, although more diversified across therapeutic areas.

Emerging players

• Alvotech: Iceland-based pure-play biosimilar developer with pan-European commercialization partnerships—comparable to Zentiva's biosimilar ambitions via mAbxience and Lupin partnerships.
• Lupin: Indian-headquartered global generic pharma with a growing biosimilar franchise—comparable to Zentiva (and a Zentiva licensing partner via the Lupin TNF-alpha biosimilar) across generic APIs and biosimilars.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@ZentivaSlovensko
• LinkedInlinkedin.com/company/zentiva-slovakia

Compliance15 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zentiva